Clinical Trials

Study Title:
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Abirami Sivapiragasam, at sivapira@musc.edu. Study Coordinator, Margaret (Maggie) Scott, at scotmarg@musc.edu. Trial opened at the following institutions: Medical University of South Carolina